George Siber, MD is an infectious disease trained physician with 40 years’ experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar7 and 13, the first pneumococcal conjugate vaccines, Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber currently is a Co-founder and Board Member of Affinivax and serves on the BOD of Genocea. Dr. Siber serves on the SABs of CureVac, ILiAD, Valneva, Vaxess, AdVaccine and Clover. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology.
Liming Li, a distinguished professor and doctoral supervisor of PKU Boya who obtains the special allowance of the State Council and is currently the president of the school of public health and major epidemic prevention and control of Peking University. Dr. Li worked successively as Assistant to the President of Peking University, President of Chinese Academy of Preventive Medicine, the first Director-General of Chinese Center for Disease Control and Prevention (CDC), Secretary of the Party committee of Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC); National inspector of the Ministry of Education, Convener of Public Health and Preventive Medicine Discipline Evaluation Group of the State Council, Chairman of the Public Health and Preventive Medicine Committee of the Ministry of Education Steering Committee for Medical Education, Vice Chairman of Working Committee for the Accreditation of Medical Education of Ministry of Education; Chairman of the Chinese Society of Medical Education of Chinese Medical Association, Vice President of Chinese Preventive Medical Association (CPMA), and Chairman of Association of Epidemiology of Chinese Preventive Medicine Association (AECPMA). Prof. Li has been engaged in the large population cohort study, chronic disease epidemiology, and geriatric epidemiology for a long time. He is Chief Editors for both the Chinese Journal of Epidemiology (in Chinese) and Global Health Journal (in English). He has co-authored over 450 papers published in peer-reviewed journals in Chinese and English. He received Eisenhower Fellowship Award in 1997 and the Johns Hopkins Society of Scholars Award in 2006. He was awarded Honorary Fellow of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom (HonFFPH) in 2010, and Academician of International Eurasian Academy of Sciences (IEAS) in 2017.
Luis Barreto, PhD has more than 30 years of experience in the fields of public policy, government relations, scientific, medical, clinical development, regulatory affairs and global health. Dr. Barreto joined Sanofi Pasteur (then known as Connaught Laboratories Limited) in 1988, where he held a number of positions including director and vice president and spent more than 23 years in research and development, clinical trials and immunization policy advice. Dr. Barreto has been president at Dr. Luis Barreto & Associates since 2011, strategic adviser at NEOMED-LABS Inc. since March 2016 and senior scientific adviser at Inventprise LLC since March 2016. Dr. Barreto graduated from Bangalore University in India with the degrees of bachelor of medicine and bachelor of surgery in August 1976. He obtained his doctor of medicine degree from the University of Nagpur in India in November 1979 and his master in health sciences from the University of Toronto in June 1983.
David Briles, PhD is renowned expert on protein-based Pneumococcal vaccines. He serves as Professor of Microbiology at the University of Alabama at Birmingham, USA. He did his graduate work on the genetic regulation of antibody binding site structure at The Rockefeller University in New York City. Dr. Briles' postdoctoral studies, with Dr. Joseph Davie at Washington University Medical School in St. Louis, dealt with the expression of antibody diversity in antibacterial antibody responses and the genetic control of susceptibility of mice to Salmonella and pneumococcal infection. He joined the UAB faculty in 1978. His research is on the molecular biology and genetics of bacterial pathogenesis, bacterial vaccines, and epidemiology of bacterial infections. Together with other colleagues at UAB and past trainees he was awarded a number of patents on pneumococcal vaccine antigens. His present studies are on protein virulence factors of pneumococci, their mechanisms of action and potential use in vaccines. In recent years his lab worked to develop surrogate assays for protective immunity to pneumococcal protein antigens. Dr. Briles has served on several study sections at the NIH and FDA and several editorial boards. He has been an advisor about the potential of pneumococcal proteins as human vaccine to the WHO, PAHO, FDA, and the PATH foundation. Dr. Briles has been a visiting faculty member at SungKyunKwan University in South Korea. He is also an Adjunct Professor at Northern Illinois University, DeKalb, Illinois.
Jingren Zhang serves as the Present Professor and Assistant Dean of Tsinghua University School of Medicine. His laboratory works on the molecular mechanisms of acute bacterial pneumonia and related diseases. He mainly focuses on the following topics, namely the bacterial genes and functions that enable the pathogens to survive and replicate in the host environment, the host cells and molecules that are able to kill non-pathogenic microbes but not the pathogens, the gaps in the host innate immune surveillance that allows the survival and replication of the pathogens (but not commensals). The answers to these questions will identify bacterial virulence factors and bridge immunity gaps that can be used to develop novel markers for pneumonia diagnosis and new therapeutics for pneumonia treatment and prevention. Jingren Zhang obtained the bachelor degree from Gansu Agricultural University and the master degree from National Standard Institute for Veterinary Bio-Products. He got his doctorate from University of Texas Health Science Center-Houston. From 1998 to 2000, he obtained postdoctoral from St. Jude Children’s Research Hospital. Dr. Zhang used to successively served as instructor in China Agricultural University, associate Professor from Albany Medical College. In 2007, he was appointed as visiting professor of the Institute of Microbiology, Chinese Academy of Sciences. He also received The National Science Fund for Distinguished Young Scholars (Class B) in the same year.